A busy morning of corporate updates dominated the premarket, with Bodycote (LSE:BOY) surging nearly 20% after reaffirming its full-year outlook and flagging improved operating margins, while Nanoco Group surprised the market by proposing to delist from the London Stock Exchange entirely. Elsewhere, strong trading updates from Scottish Mortgage and Zotefoams (LSE:ZTF) added to a constructive tone across the small- and mid-cap space.
Bodycote reaffirms FY26 margin improvement outlook
Bodycote (LSE:BOY) confirmed it expects to deliver core organic revenue growth alongside improved operating margins for the full year. The company cited year-to-date trading and continued strategic progress as the basis for its confidence, offering investors a reassurance that had evidently been in short supply heading into the update.
Nanoco proposes full delisting and private re-registration
Nanoco Group (LSE:NANO) announced plans to cancel its Main Market listing and re-register as a private company. The quantum dot specialist said the move would cut costs, preserve cash, and allow it to pursue commercialisation without the disclosure obligations and expense burden of a public listing. The proposal will require shareholder approval before it can proceed.
Scottish Mortgage posts 27% NAV return ahead of SpaceX IPO
Scottish Mortgage Investment Trust (LSE:SMT) reported a 27.4% net asset value total return for the year to 31 March, comfortably ahead of the FTSE All-World Index's 18.0% gain over the same period. The trust's private holdings, which include a significant position in SpaceX, have attracted growing attention as the prospect of a SpaceX IPO draws closer, with the anticipated listing seen as a potential catalyst for further NAV uplift.
Zotefoams keeps full-year guidance after 26% revenue jump
Zotefoams (LSE:ZTF) reported a 26% rise in four-month revenue and maintained its full-year objectives, with Group CEO Ronan Cox pointing to a strong balance sheet and continued demand across key target markets. The polyolefin foams manufacturer said it remained confident in delivering on its stated goals for the year.
Deltic Energy receives US$1m Dana Petroleum farm-out payment
Deltic Energy (LSE:DELT) confirmed receipt of a US$1m payment from Dana Petroleum, representing cost reimbursement under the farm-out agreement for the Selene Prospect in the North Sea. The cash injection provides a modest but meaningful boost to the small-cap explorer's balance sheet as it advances its offshore programme.
Sundae Bar books first revenues after marketplace launch
Sundae Bar (AIM:SBAR) reported its first half-year results since going live with its marketplace platform, confirming it recognised its first revenues in the period following the launch of both a live marketplace and an Enterprise Offering. The AIM-listed enterprise software company gave no specific revenue figure in its headline update, but the milestone marks a transition from pre-revenue development stage to active commercial operations.
Watkin Jones revenue slips to £100.2m amid slower activity
Watkin Jones (AIM:WJG) reported half-year revenue of £100.2m, down on the prior period as activity levels slowed across its development pipeline. Chief Executive Alex Pease pointed to the group's integrated platform as a differentiator, highlighting its ability to identify incremental opportunities and diversify revenue streams.
Hollywood Bowl lifts H1 revenue and backs FY26 expectations
Hollywood Bowl Group (LSE:BOWL) reported higher first-half revenue and said it remained confident in delivering on full-year expectations. Chief Executive Stephen Burns credited the resilience of the group's value-led offer and disciplined cost management for the positive momentum. The tenpin bowling operator gave no specific revenue figure in its headline statement but said customer demand remained robust heading into the second half.
Pets at Home backs outlook despite profit decline
Pets at Home Group (LSE:PETS) reported a drop in profits but said it remained comfortable about meeting market expectations for the year. Chief Executive James Bailey outlined a strategy centred on profitable volume-led growth in retail, continued execution of the vet business's growth levers, and the forthcoming launch of an insurance offering. The group framed the profit decline as a transitional period ahead of a broader commercial build-out.
FDA extends review deadline for AstraZeneca's camizestrant filing
AstraZeneca (LSE:AZN) said the US Food and Drug Administration had extended the Prescription Drug User Fee Act decision date for its camizestrant combination filing, to allow time for review of additional analyses linked to the SERENA-6-based NDA. The extension is procedural rather than a signal of concern, but it pushes back the timeline for a potential approval of the oral selective oestrogen receptor degrader.
